Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Type-1 Diabetes Mellitus Clinical Trial

Official title: Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus

Status Completed

Clinical Trial Summary

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type-1 Diabetes Mellitus

• NCT number: NCT00603031
• Study type: Interventional
• Source: Hvidovre University Hospital
• Status: Completed
• Phase: N/A
• Start date: January 2008
• Completion date: June 2008